Abnormal Screening Results: What Happens Next

An abnormal screening result does not establish a cancer diagnosis — it signals that additional evaluation is warranted. This page explains what "abnormal" means across major screening modalities, how the follow-up process unfolds in structured clinical steps, and where the clinical decision boundaries fall between observation, diagnostic workup, and intervention. Understanding these distinctions helps patients and families interpret provider recommendations accurately.

Definition and Scope

Screening tests are designed for asymptomatic populations and are calibrated to detect signals — not to confirm disease. An abnormal result means the test output fell outside the defined reference range or threshold set by the screening protocol, not that cancer is present. The U.S. Preventive Services Task Force (USPSTF) publishes grade-based recommendations that define both who should be screened and what thresholds trigger follow-up action.

False-positive rates vary substantially by test and population. For mammography, the USPSTF notes that among women screened annually over 10 years, approximately 61% will experience at least one false-positive recall (USPSTF, 2024 Breast Cancer Screening Recommendation). For lung cancer low-dose CT (LDCT) screening, the National Lung Screening Trial reported a false-positive rate of approximately 96% among positive screens — meaning the vast majority of flagged findings did not result in a cancer diagnosis (National Cancer Institute, National Lung Screening Trial). These figures establish why the pathway from abnormal result to confirmed diagnosis involves multiple discrete steps rather than immediate intervention.

The regulatory context for oncology that governs these protocols spans Centers for Medicare & Medicaid Services (CMS) coverage criteria, FDA-cleared device standards, and professional society guidelines from bodies such as the American College of Radiology (ACR) and the American Cancer Society (ACS).

How It Works

The follow-up sequence after an abnormal screen is not uniform — it depends on the screening modality, the nature of the finding, and the patient's clinical profile. The general framework proceeds through five phases:

  1. Result classification — The screening result is categorized using a standardized reporting system. For mammography, the ACR's BI-RADS (Breast Imaging Reporting and Data System) assigns categories from 0 (incomplete, needs additional imaging) through 6 (biopsy-confirmed malignancy). A BI-RADS 3 finding carries an estimated malignancy risk of less than 2% and typically triggers short-interval follow-up rather than immediate biopsy (ACR BI-RADS Atlas, 5th Edition).

  2. Supplemental imaging — Abnormal screens frequently lead to diagnostic imaging rather than immediately to tissue sampling. A suspicious mammogram may be followed by a diagnostic mammogram, targeted ultrasound, or MRI. An abnormal LDCT result is classified using the Lung-RADS system, also developed by the ACR.

  3. Tissue sampling — When imaging confirms a finding that meets threshold criteria, a biopsy is ordered. Biopsy type — core needle, fine needle aspiration, or surgical excision — is determined by lesion location, size, and accessibility.

  4. Pathological review — Tissue is analyzed by a pathologist who produces a pathology report classifying the tissue as benign, precancerous, or malignant. Cancer staging and grading follows confirmed malignant findings.

  5. Multidisciplinary planning — Confirmed cancers are reviewed by tumor boards in most accredited cancer programs, integrating oncology, radiology, pathology, and surgery to establish a treatment plan.

Common Scenarios

Different screening modalities generate distinct categories of abnormal results with different clinical trajectories.

Mammography: A BI-RADS 0 recall for additional imaging is the most common abnormal result and frequently resolves with diagnostic views. BI-RADS 4 (suspicious) and 5 (highly suggestive of malignancy) findings proceed to biopsy. Findings in these categories span a wide range — BI-RADS 4 is subdivided into 4A, 4B, and 4C, with malignancy probability ranging from greater than 2% to less than 95%.

Colorectal screening: A positive fecal immunochemical test (FIT) or stool DNA test is not diagnostic — it mandates colonoscopy. The USPSTF colorectal cancer screening recommendation specifies that a positive non-invasive test must be followed by colonoscopy to complete the diagnostic process. Polyps found during colonoscopy are classified by histology: hyperplastic polyps carry minimal malignancy risk, while adenomas — particularly those larger than 10 mm or with high-grade dysplasia — require complete removal and surveillance.

Cervical screening: The Bethesda System standardizes reporting of Pap test results. An ASC-US (atypical squamous cells of undetermined significance) result in a patient who tests positive for high-risk HPV types triggers colposcopy. An HSIL (high-grade squamous intraepithelial lesion) finding proceeds directly to colposcopy and possible biopsy regardless of HPV status.

PSA elevation: Prostate-specific antigen (PSA) elevation prompts risk stratification using tools such as the Prostate Imaging Reporting and Data System (PI-RADS) on MRI before biopsy decisions are made. The oncology main resource index covers the full range of cancer evaluation pathways.

Decision Boundaries

Clinical decision-making at each stage is governed by risk thresholds, not binary positive/negative designations. Key boundaries include:

Patients navigating an abnormal result who need to understand their options for getting help through the oncology system will encounter these structured decision points at each stage of evaluation.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)